NCT03242915

Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents

Phase II Study of Pembrolizumab in Combination With Platinum-based Chemotherapy in Nonsmall Cell Lung Cancer Patients With Targetable Genetic Alterations Previously Treated With Appropriate Targeted Agents With Progressive Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: University of Michigan Rogel Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Investigators hypothesize that addition of pembrolizumab will enhance the efficacy of carboplatin and pemetrexed in patients with EGFR-mutation-positive NSCLC, or patients with other genetic alterations, and who have disease progression following appropriate targeted therapies.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Pembrolizumab	200mg IV every 3 weeks
DRUG	Carboplatin	AUC 5 IV every 3 weeks
DRUG	Pemetrexed	500 mg/m\^2 IV every 3 weeks

Timeline

• Start date: 2017-10-03
• Primary completion: 2025-02-20
• Completion: 2025-02-20
• First posted: 2017-08-08
• Last updated: 2025-05-30
• Results posted: 2025-05-30

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study